
Martin Olin appointed new Chairman of the Board in AcouSort

During the Annual General Assembly held today, April 28th, Martin Olin was elected new Chairman of the Board in AcouSort. Martin has more than two decades of experience from executive positions in international life science and life science investment companies and has held board positions in several life science companies.

Martin Olin has held executive positions as CEO, CFO or Director in international life science companies Novo Nordisk and Symphogen A/S and has over the years held numerous board assignments in the Nordics as well as international enterprises. Since 2020, he holds the position as CEO of Danish venture capital firm Nordic Eye.

– We are very happy to welcome Martin Olin as new Chairman of the Board. With his vast experience from prominent executive positions and board assignments combined with a strong network within life science, pharma and investment banks, his appointment is a very important addition for the continued realization of our growth ambitions. I very much look forward to working with Martin and the rest of the Board to continue developing AcouSort towards our goal of becoming the preferred provider of automated sample preparation modules for the life science industry. I also want to thank our resigning Chairman, Martin Linde for his significant contributions to AcouSort's growth and development over the past six years, says AcouSort's CEO Torsten Freltoft.

- AcouSort is well positioned to become the preferred provider of automated sample preparation within the life science industry and I look very much forward to joining the Board of Directors and executing on the company strategy and potential., says Martin Olin.

Martin Olin will be replacing Martin Linde, who is resigning as Chairman of the Board to focus on his role as CEO of AegirBio AB. Martin Linde has been elected as member of the Board in AcouSort for a transitional period.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.